Praneet Iyer, MD
Critical Care Medicine · Roanoke, VANPI 1023435609
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $446 and has fallen 78.0% since, to $98 in 2024.
Across 62 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$270
- GSK$247
- Mallinckrodt Hospital Products Inc.$152
- Johnson & Johnson$102
- Actelion Pharmaceuticals US, Inc.$81
- Edwards Lifesciences$56
- plus $464 from 18 others
What the payments were for
- Food & beverage$1,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $270 |
| GSK | 16 | $247 |
| Mallinckrodt Hospital Products Inc. | 3 | $152 |
| Johnson & Johnson | 1 | $102 |
| Actelion Pharmaceuticals US, Inc. | 5 | $81 |
| Edwards Lifesciences | 1 | $56 |
| La Jolla Pharmaceutical Company | 3 | $54 |
| Genentech USA, Inc. | 3 | $51 |
| Boehringer Ingelheim | 3 | $51 |
| Ambu Inc. | 2 | $39 |
| Advanced Respiratory, Inc | 2 | $34 |
| Pinnacle Biologics, Inc | 1 | $28 |
| Novartis | 1 | $24 |
| Grifols USA, LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Merck | 1 | $15 |
| Sanofi | 1 | $14 |
| Amgen | 1 | $13 |
| Bayer | 1 | $13 |
| Insmed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,372 in reported general payments places this provider in the 75th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 20 | $379,864 |
| Dupixent PenDupilumab | 64 | $244,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 234 | $161,795 |
| Dupixent SyringeDupilumab | 11 | $39,325 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $30,629 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $28,874 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $22,678 |
| Spiriva HandihalerTiotropium Bromide | 30 | $21,753 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $20,045 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $17,068 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,141 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,647 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,393 |
| DuleraMometasone/Formoterol | 21 | $7,109 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $81 | $379,86420 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $247 | $227,783371 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $51 | $36,78174 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $270 | $23,78857 claims |
| MerckDulera | $15 | $7,10921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Roanoke
- Oksana ShlobinFalls Church$375K
- Matthew WilliamsAnnandale$235K
- Sami Abdul JawadFalls Church$193K
- Rajiv MalhotraRichmond$187K
- Thomas BouderWinchester$163K
- Christopher KingFalls Church$131K
- Rohit GoyalFredericksburg$95K
- Robert ThieleCharlottesville$52K
- Jeff HalesArlington$37K
- Paul MarikNorfolk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.